Eli Lilly and Company
Eli Lilly Q1 2025 Financial Results: Significant Revenue Growth and Pipeline Updates
Summary
Eli Lilly reported Q1 2025 financial results with a 45% increase in revenue to $12.73 billion, driven by strong sales of Mounjaro and Zepbound. Earnings per share (EPS) increased 23% to $3.06 on a reported basis and 29% to $3.34 on a non-GAAP basis. The company reaffirmed its revenue guidance for 2025 between $58.0 billion and $61.0 billion. Pipeline progress included positive Phase 3 trial results for orforglipron in Type 2 diabetes.
Profitelligence Alerts
Get alerts for LLY
Be first to know when Eli Lilly and Company files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Eli Lilly and Company
Eli Lilly and Company is a renowned pharmaceutical corporation that engages in the discovery, development, manufacturing, and marketing of pharmaceutical products worldwide. The company's core purpose is to create high-quality medications that address significant medical needs in areas such as oncology, immunology, neuroscience, and endocrinology. Eli Lilly is particularly noted for its pioneering work in diabetes care with products like insulin and for its innovative approach to treating complex health conditions. With a history dating back to 1876, the Indianapolis-based company blends scientific innovation with a commitment to improve patient outcomes. Eli Lilly’s role in the financial markets is significant due to its contributions to healthcare advancements and its influence on global pharmaceutical trends. The company's robust pipeline and emphasis on research and development underscore its potential to impact healthcare solutions and deliver sustainable growth. Its products and services are marketed globally, underlying its importance in the biopharmaceutical industry.
Official SEC Documents
Advertisement